136 related articles for article (PubMed ID: 15308571)
1. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.
Dhodapkar MV; Hussein MA; Rasmussen E; Solomon A; Larson RA; Crowley JJ; Barlogie B;
Blood; 2004 Dec; 104(12):3520-6. PubMed ID: 15308571
[TBL] [Abstract][Full Text] [Related]
2. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement.
Dietrich S; Schönland SO; Benner A; Bochtler T; Kristen AV; Beimler J; Hund E; Zorn M; Goldschmidt H; Ho AD; Hegenbart U
Blood; 2010 Jul; 116(4):522-8. PubMed ID: 20375312
[TBL] [Abstract][Full Text] [Related]
3. Treatment of AL-amyloidosis with dexamethasone plus alpha interferon.
Dhodapkar MV; Jagannath S; Vesole D; Munshi N; Naucke S; Tricot G; Barlogie B
Leuk Lymphoma; 1997 Oct; 27(3-4):351-6. PubMed ID: 9402333
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study.
Moreau P; Jaccard A; Benboubker L; Royer B; Leleu X; Bridoux F; Salles G; Leblond V; Roussel M; Alakl M; Hermine O; Planche L; Harousseau JL; Fermand JP
Blood; 2010 Dec; 116(23):4777-82. PubMed ID: 20724537
[TBL] [Abstract][Full Text] [Related]
5. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
[TBL] [Abstract][Full Text] [Related]
6. [Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
Pika T; Lochman P; Vymětal J; Metelka R; Minařík J; Látalová P; Zapletalová J; Bačovský J; Ščudla V
Klin Onkol; 2013; 26(5):343-7. PubMed ID: 24107157
[TBL] [Abstract][Full Text] [Related]
7. Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis.
Sanchorawala V; Seldin DC; Berk JL; Sloan JM; Doros G; Skinner M
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):469-72. PubMed ID: 21156464
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients.
Tazawa K; Matsuda M; Yoshida T; Gono T; Katoh N; Shimojima Y; Ishii W; Fushimi T; Koyama J; Ikeda S
Intern Med; 2008; 47(17):1517-22. PubMed ID: 18758127
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.
Lamm W; Willenbacher W; Lang A; Zojer N; Müldür E; Ludwig H; Schauer-Stalzer B; Zielinski CC; Drach J
Ann Hematol; 2011 Feb; 90(2):201-6. PubMed ID: 20821326
[TBL] [Abstract][Full Text] [Related]
10. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Hazenberg BP; Croockewit A; van der Holt B; Zweegman S; Bos GM; Delforge M; Raymakers RA; Sonneveld P; Vellenga E; Wijermans PW; von dem Borne PA; van Oers MH; de Weerdt O; Spoelstra FM; Lokhorst HM;
Haematologica; 2015 May; 100(5):677-82. PubMed ID: 25661441
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Cibeira MT; Oriol A; Lahuerta JJ; Mateos MV; de la Rubia J; Hernández MT; Granell M; Fernández de Larrea C; San Miguel JF; Bladé J;
Br J Haematol; 2015 Sep; 170(6):804-13. PubMed ID: 25974382
[TBL] [Abstract][Full Text] [Related]
12. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP;
N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669
[TBL] [Abstract][Full Text] [Related]
13. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
15. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
16. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis.
Gertz MA; Lacy MQ; Lust JA; Greipp PR; Witzig TE; Kyle RA
Med Oncol; 1999 Jul; 16(2):104-9. PubMed ID: 10456658
[TBL] [Abstract][Full Text] [Related]
18. Effective and well tolerated treatment with melphalan and dexamethasone for primary systemic AL amyloidosis with cardiac involvement.
YOSHIZAWA S; AKAHANE D; FUJIMOTO H; GOTOH M; KIGUCHI T; TAUCHI T; OHYASHIKI K
Rinsho Ketsueki; 2009 Nov; 50(11):1647-51. PubMed ID: 20009442
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.
Hegenbart U; Bochtler T; Benner A; Becker N; Kimmich C; Kristen AV; Beimler J; Hund E; Zorn M; Freiberger A; Gawlik M; Goldschmidt H; Hose D; Jauch A; Ho AD; Schönland SO
Haematologica; 2017 Aug; 102(8):1424-1431. PubMed ID: 28522573
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.
Wechalekar AD; Goodman HJ; Lachmann HJ; Offer M; Hawkins PN; Gillmore JD
Blood; 2007 Jan; 109(2):457-64. PubMed ID: 16990593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
